Bristol Myers Squibb stock holds steady after Q2 2026 growth and guidance hike
Published on 08/29/2026 at 06:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol Myers Squibb (ISIN US0897961004) stock was quoted in the mid-$60 range at the close of August 28, 2026, with a last regular-session price of $66.58 before a slight after-hours uptick to $66.60, according to recent market data as of August 28, 2026 4:00 p.m. ET. The same quote snapshot shows the shares down $0.37 on the day for a 0.55 percent decline, keeping the stock trading modestly above several fair-value estimates discussed in current valuation commentary.
Q2 2026 results lift earnings and revenue
Recent reporting on Bristol Myers Squibb’s latest quarterly figures indicates that in Q2 2026 the company generated revenue of $12.97 billion, representing 6 percent year-over-year growth, or 5 percent when adjusted for foreign exchange effects. The same overview notes that the company’s growth portfolio delivered $7.6 billion in sales in Q2 2026, which is a 15 percent increase compared with the prior-year quarter and underscores how newer products are gaining traction faster than the overall business.
In contrast, the legacy portfolio generated $5.4 billion in Q2 2026 revenue, down 4 percent year-over-year as older medicines face generic and biosimilar competition, highlighting the shift in Bristol Myers Squibb’s revenue mix. Per the same Q2 2026 summary, non-GAAP earnings per share reached $2.04 versus $1.46 in Q2 2025, while GAAP EPS rose to $1.62, showing that earnings grew materially faster than revenue as margins benefited from the higher contribution of newer, higher-growth therapies.
Full-year 2026 guidance raised on portfolio momentum
Building on the Q2 2026 performance, Bristol Myers Squibb raised its full-year 2026 revenue guidance to a range of $49.0 billion to $50.0 billion, up from a previous range of $46.0 billion to $47.5 billion, according to the same earnings commentary. That upgrade implies a mid-point uplift of $2.75 billion relative to the former guidance midpoint and signals management’s increased confidence in demand for its key therapies over the remainder of 2026.
Alongside the revenue outlook, the company also increased its full-year 2026 non-GAAP EPS guidance to a range of $6.75 to $7.00, as cited in the same Q2 2026 review, pointing to expectations for continued margin resilience and cost discipline. For investors comparing these targets with the latest quarterly run-rate, the Q2 2026 non-GAAP EPS figure of $2.04, if annualized without seasonality, would equate to more than $8 on a full-year basis, which leaves some room for potential quarter-to-quarter variability relative to the official guidance range.
Valuation context for Bristol Myers Squibb stock
Current valuation commentary notes that widely followed fair-value models place Bristol Myers Squibb’s intrinsic value close to the low $60s per share, with one referenced estimate at $62.96, slightly below the stock’s recent closing level of $66.95 highlighted in the same analysis. That narrative underscores that at the recent price the shares are trading a few dollars above that fair-value marker, which still leaves a relatively modest premium compared with some faster-growing biotech peers.
For context, the quote data from August 28, 2026 also show Bristol Myers Squibb shares opening that day at $66.93 on the New York Stock Exchange, as highlighted in a recent institutional-holding update. The same filing summary describes the price performance backdrop for new institutional positions and indicates that the stock remains in the mid-$60 band, which is relatively close to the fair-value estimates discussed in the valuation commentary.
Key therapies underpinning the growth portfolio
The Q2 2026 revenue breakdown highlights a group of newer therapies that management clusters as the growth portfolio, and these assets are central to Bristol Myers Squibb’s long-term story. The same Q2 2026 write-up cites medicines such as the immuno-oncology agent Opdivo Qvantig, the anemia treatment Reblozyl, the cardiomyopathy drug Camzyos, the cell therapy Breyanzi, and the combination regimen Opdualag as important contributors to the 15 percent growth portfolio sales increase to $7.6 billion.
Alongside these internal products, Bristol Myers Squibb continues to support external innovation, including milestone payments to partners whose platforms could complement the company’s own pipeline, as highlighted by recent discussion of a $15 million milestone payment connected to an RNA platform collaboration. By diversifying revenue sources across oncology, cardiovascular disease, and hematology, the company aims to offset ongoing declines in its legacy portfolio, which saw a 4 percent revenue drop to $5.4 billion in Q2 2026 compared with Q2 2025.
Bristol Myers Squibb stock and patent-cliff backdrop
The broader pharmaceutical sector is currently navigating one of the largest patent-cliff cycles in decades, where major drugs face loss of exclusivity and swift generic erosion. A recent industry overview notes that annual sales worth many billions of dollars can vanish in less than a year once generics arrive, underscoring the importance of replenishing pipelines and accelerating new launches. That sector analysis frames the environment in which Bristol Myers Squibb’s mix shift toward its growth portfolio should be viewed.
Against that backdrop, Bristol Myers Squibb’s 6 percent revenue growth in Q2 2026 and its 15 percent growth portfolio expansion indicate that the company is currently managing the transition with a healthier trajectory than some legacy-focused peers that are more exposed to steep patent expiries. For investors assessing the durability of the raised $49.0 billion to $50.0 billion full-year 2026 revenue guidance, the key question is whether double-digit growth from newer therapies can continue to more than offset the 4 percent decline in the $5.4 billion legacy portfolio recorded in Q2 2026.
Representative product: Camzyos in cardiomyopathy
Among Bristol Myers Squibb’s newer therapies, the cardiomyopathy drug Camzyos stands out as a representative example of the company’s strategy to build leadership positions in specialized, high-value indications. Recent Q2 2026 commentary groups Camzyos within the growth portfolio that collectively reached $7.6 billion in quarterly sales, up 15 percent year-over-year, signaling strong adoption trends for this and other newer medicines aimed at diseases with significant unmet need.
Camzyos is used in the treatment of certain forms of obstructive hypertrophic cardiomyopathy, a condition where thickened heart muscle can impair blood flow out of the heart and cause symptoms such as shortness of breath, chest pain, and fatigue. By targeting the underlying mechanics of cardiac muscle contraction, Camzyos is designed to improve functional capacity and quality of life for eligible patients, and its contribution to the growth portfolio helps illustrate how Bristol Myers Squibb is increasingly relying on innovative, specialty therapies to drive its 2026 and longer-term revenue trajectory.
Recent share price level and investor takeaway
Based on the most recent quote snapshot for Bristol Myers Squibb on the New York Stock Exchange as of August 28, 2026 4:00 p.m. ET, the stock closed at $66.58 with a modest 0.55 percent decline on the day and then ticked to $66.60 in after-hours trading, leaving the shares slightly above one cited fair-value estimate of $62.96. For investors, that pricing suggests that the market currently values Bristol Myers Squibb at a measured premium to conservative valuation models while recognizing the firm’s Q2 2026 revenue growth of 6 percent year-over-year, the 15 percent expansion of its $7.6 billion growth portfolio, and the upgraded full-year 2026 guidance to $49.0 billion to $50.0 billion in revenue and $6.75 to $7.00 in non-GAAP EPS.
Company facts
Company: Bristol Myers Squibb
ISIN: US0897961004
Ticker: BMY
Exchange: New York Stock Exchange
Price (as of August 28, 2026, 4:00 p.m. ET): $66.58 USD
Sector / Industry: Pharmaceuticals / Biotechnology
Index membership: S&P 500
